European Cystic Fibrosis Pharmacy Group (ECFPG)

Year of report: 2023	
	Date of initial approval of Special Interest Group: 2015

Coordinator name: Maarten Ploeger

Long term aims of the Special Interest Group including estimated achievement date:

The mission statement of the European Cystic Fibrosis Pharmacy Group is to promote good practice in the supply of, and equitable access to, medicines and information about medicines to patients; set high standards of pharmacy practice; support patients to achieve greatest benefit from their medicines; promote the role of pharmacists and affiliated professions in the pharmaceutical care of patients with CF; to deliver continuing professional education and development, and pharmacy practice research.

Outcomes already achieved:

- Publication of the ECFS Standards of Care book: Optimising Pharmaceutical Care in Cystic Fibrosis in 2020, which many members of the group contributed to. With increasing complexities surrounding choice of medicine, drug interactions, dose and formulation, this was an opportunity to use the expertise of our members to improve patient care. It also served to highlight the important role that the CF clinical pharmacist has to play within the CF MDT in managing the challenges of medicines optimisation in pwCF.
- Expanding membership in terms of numbers and geographical reach.
- Larger and well attended annual meetings ensuring sharing of knowledge between Pharmacy teams across Europe (and beyond).

Aims and Objectives for the year 2023-2024

Aims:
- To provide an educational meeting and networking opportunities for its membership at the ECFS 46th annual conference in June 2023.
- To promote the role and expertise of the CF pharmacist in the care of the PwCF and as a valuable member of the CF MDT.
- To finalize the Pharmacy Syllabus and education program
- Introducing the drug dosing app.

Objectives:
- To encourage its membership to participate in research activities.
- To encourage collaborative working within the group and wider CF community.

- To support members who are new to the role or those that wish to develop their skills further.

Membership

As of 05 may 2023, the European CF Pharmacy Group had 43 members. Whilst members are encouraged to join the ECFS, only 17 members included their ECFS membership number on registration forms. The remainder of applicants were emailed on receipt of their membership application form to recommend registration with ECFS but were permitted to join the mailing list for the group. We will develop a mechanism this year to cross reference those on the mailing list with those that have maintained or joined ECFS so that we can proactively encourage individuals to join the ECFS or renew their membership. Moving forward we will consider whether to remove those from our membership / mailing lists if they are not members of the ECFS. We will use the forthcoming conference meeting to again encourage membership and the benefits of being a member of the ECFS.

Aims for the coming year (please state year) (max 50 words):

The chairmanship has been transferred as of 01-01-2023. I want to use this year to take inventory of the current members and determine if they still want to remain active within the group. There are several challenges that we want to complete this year. These include finalizing the syllabus, the dosing app, and updating various sections in the standards for the care of people with CF.

Summary:

The chairmanship has been transferred as of January 1st, 2023, and this year will be used to assess current members' interest in remaining active within the group. The group faces several challenges this year, such as updating the syllabus, dosing app, and various sections in the standards for the care of people with CF. In addition to completing these challenges, the group aims to inspire and attract new members.

Breakdown of expenses (please include total amount received as well as expenditure and, if applicable, the outstanding balance (Euros):
There are no expenses know for now

Budget amount requested for next year (please give the amount in Euros and the year):

nil